Clinical Trial Update: An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating efficacy, safety, and pharmacokinetics of JNJ-56136379 in chronic hepatitis B patients has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• JNJ-56136379

Snippet

Sponsor: Janssen Sciences Ireland UC | Conditions: Hepatitis B | Phase 2 | Status: COMPLETED | Results posted: 2022-11-17